1. Home
  2. GANX vs PFD Comparison

GANX vs PFD Comparison

Compare GANX & PFD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gain Therapeutics Inc.

GANX

Gain Therapeutics Inc.

HOLD

Current Price

$2.08

Market Cap

159.2M

Sector

Health Care

ML Signal

HOLD

Logo Flaherty & Crumrine Preferred and Income Fund Incorporated

PFD

Flaherty & Crumrine Preferred and Income Fund Incorporated

HOLD

Current Price

$11.83

Market Cap

152.5M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
GANX
PFD
Founded
2017
1990
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
159.2M
152.5M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
GANX
PFD
Price
$2.08
$11.83
Analyst Decision
Strong Buy
Analyst Count
6
0
Target Price
$8.00
N/A
AVG Volume (30 Days)
1.3M
33.2K
Earning Date
11-12-2025
01-01-0001
Dividend Yield
N/A
6.30%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.41
$8.53
52 Week High
$4.34
$11.18

Technical Indicators

Market Signals
Indicator
GANX
PFD
Relative Strength Index (RSI) 39.13 49.00
Support Level $1.75 $11.67
Resistance Level $2.26 $12.07
Average True Range (ATR) 0.29 0.14
MACD -0.06 -0.01
Stochastic Oscillator 21.75 40.42

Price Performance

Historical Comparison
GANX
PFD

About GANX Gain Therapeutics Inc.

Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.

About PFD Flaherty & Crumrine Preferred and Income Fund Incorporated

Flaherty & Crumrine Prefd Inc Fund Inc is a United States-based diversified, closed-end management investment company. Its investment objective is to provide its common shareholders with high current income consistent with the preservation of capital. The fund invests in a diversified portfolio of preferred securities, which includes traditional preferred stocks eligible for the inter-corporate dividends received a deduction and fully taxable preferred securities.

Share on Social Networks: